ENYO Pharma in the Top 50 of the EIC ScalingUp List
ENYO Pharma is in the Top 50 of the EIC ScalingUp List, in the Health Track. We were selected out of a universe of 3,000+ deeptech startups, as funded so far by the European Innovation Council (EIC) or SME Instrument. This is a fantastic business support for the growth of the company during this pivotal year.
5th NASH Summit 2021
November 29 – December 2, 2021
100% digital
Dr Pietro Scalfaro, CMO of the company, will present latest Vonafexor data at the 5th NASH Summit. This conference aims at deepening understanding of early, translational and late stage clinical science to support NASH candidate entry to market.
Selection in the Best of the Liver Meeting 2021
ENYO Pharma has been highlighted in the “Best of The Liver Meeting 2021” for the oral presentation describing Vonafexor’s key effects after 12 weeks of treatment on liver and kidney functions in NASH patients, given by the LIVIFY Principal Investigator Pr Stephen Harrison during the Late Breaking Session 1 Sunday, November the 14th.
EASL – International Liver Congress 2022
22-26 June, 2022
London, UK.
ENYO Pharma will attend the EASL International Liver Congress at London in April 2022.
International Workshop on HBV Cure 2021 (Sponsorship)
Virtual Event
9-10 November 2021
ENYO Pharma sponsors and attends the International Workshop on HBV Cure 2021 organized by Virology Education in close collaboration with the Toronto Centre for Liver Disease and chaired by Drs. Harry Janssen and Adam Gehring, the International Workshop on HBV Cure.
https://academicmedicaleducation.com/hbv-cure-2021/
Latest Press Release 